The role of erythropoietin in myocardial protection: Potential mechanisms and applications

Expert Review of Cardiovascular Therapy

Volumn 4, Issue 1, 2006, Pages 41-50

  Schwartzenberg, Shmuel ^a   Ben Shoshan, Jeremy ^a   Keren, Gad ^a   George, Jacob ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Angiogenesis; Biomarker; Congestive heart failure; Erythropoietin; Ischemiareperfusion model; Ischemic heart disease; Receptor

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; DIURETIC AGENT; DOXORUBICIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FUROSEMIDE; HEMOGLOBIN; IRON; JANUS KINASE; NITRIC OXIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; PROTEIN KINASE C; RECOMBINANT ERYTHROPOIETIN; STAT PROTEIN; WORTMANNIN;

ANEMIA; ANGIOGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERTENSION; HYPERVISCOSITY SYNDROME; NONHUMAN; PLEIOTROPY; PROGNOSIS; PROTEIN FUNCTION; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; ERYTHROPOIETIN; HUMANS; MYOCARDIUM; RECEPTORS, ERYTHROPOIETIN;

EID: 33646193093     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.4.1.41     Document Type: Review

References (110)

1. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 293(1), 90-95 (2005).
2. Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc. Res. 59(3), 538-548 (2003).
3. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end stage renal disease with recombinant human erythropoietin. Results of a combined Phase I and II clinical trial. N. Engl. J. Med. 316(2), 73-78 (1987).
4. Lin FK, Suggs S, Lin CH et al. Cloning and expression of the human erythropoietin gene. Proc. Natl Acad. Sci. USA 82(22), 7580-7584 (1985).
5. Silverberg DS, Wexler D, Sheps D et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J. Am. Coll. Cardiol. 37(7), 1775-1780 (2001).
6. Silverberg DS, Wexler D, Blum M et al. The effect of correction of anemia in diabetics and non diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol. Dial. Transplant 18(1), 141-146 (2003).
7. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107(2), 294-299 (2003).
8. Chong ZZ, Kang JQ, Maiese K. Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J. Cereb. Blood Flow Metab. 22(5), 503-514 (2002).
9. Ehrenreich H, Hasselblatt M, Dembowski C et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med. 8(8), 495-505 (2002).
10. George J, Patal S, Wexler D et al. Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers. Arch. Intern. Med. 165(11), 1304-1309 (2005).
11. van der Meer P, Voors AA, Lipsic E, Smilde TD, van Gilst WH, van Veldhuisen DJ. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J. Am. Coll. Cardiol. 44(1), 63-67 (2005).
12. Namiuchi S, Kagaya Y, Ohta J et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J. Am. Coll. Cardiol. 45(9), 1406-1412 (2005).
13. Moon C, Krawczyk M, Ahn D et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc. Natl Acad. Sci. USA 100(20), 11612-11617 (2003).
14. Porter DL, Goldberg MA. Physiology of erythropoietin production. Semin. Hematol. 31(2), 112-121 (1994).
15. Eckardt KU, Koury ST, Tan CC et al. Distribution of erythropoietin producing cells in rat kidneys during hypoxic hypoxia. Kidney Int. 43(4), 815-823 (1993).
16. Dame C, Fahnenstich H, Freitag P et al. Erythropoietin mRNA expression in human fetal and neonatal tissue. Blood 92(9), 3218-3225 (1998).
17. Masuda S, Okano M, Yamagishi K, Nagao M, Ueda M, Sasaki R. A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J. Biol. Chem. 269(30), 19488-19493 (1994).
18. Mulcahy L. The erythropoietin receptor. Semin. Oncol. 28(2), 19-23 (2001).
19. Lacombe C. Mayeux P. Biology of erythropoietin. Haematologica 83(8), 724-732 (1998).
20. Anagnostou A, Liu Z, Steiner M et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc. Natl Acad. Sci. USA. 91(9), 3974-3978 (1994).
21. Tramontano AF, Muniyappa R, Black AD et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem. Biophys. Res. Commun. 308(4), 990-994 (2003).
22. van der Meer P, Lipsic E, Henning RH et al. Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischaemia-reperfusion injury. Eur. J. Heart Fail. 6(7), 853-859 (2004).
23. Cai Z, Manalo DJ, Wei G et al. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischaemia-reperfusion injury. Circulation 108(1), 79-85 (2003).
24. Schuster SJ, Badiavas EV, Costa-Giomi P, Weinmann R, Erslev AJ, Caro J. Stimulation of erythropoietin gene transcription during hypoxia and cobalt exposure. Blood 73(1), 13-16 (1989).
25. Jelkmann W, Hellwig-Burgel T. Biology of erythropoietin. Adv. Exp. Med. Biol. 502, 169-187 (2001).
26. Remy I, Wilson IA, Michnick SW. Erythropoietin receptor activation by a ligand-induced conformation change. Science 283(5404), 990-993 (1999).
27. Rafiee P, Shi Y, Su J, Pritchard KA Jr, Tweddell JS, Baker JE. Erythropoietin protects the infant heart against ischaemia-reperfusion injury by triggering multiple signaling pathways. Basic Res. Cardiol. 100(3), 187-197 (2005).
28. Hanlon PR, Fu P, Wright GL, Steenbergen C, Arcasoy MO, Murphy E. Mechanisms of erythropoietin-mediated cardioprotection during ischaemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling. FASEB J. 19(10), 1323-1325 (2005).
29. Cai Z, Semenza GL. Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischaemia/reperfusion injury. Circulation 109(17), 2050-2053 (2004).
30. Silva M, Benito A, Sanz C et al. Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J. Biol. Chem. 274(32), 22165-22169 (1999).
31. Baker JE. Erythropoietin mimics ischemic preconditioning. Vascul. Pharmacol. 42(5-6), 233-241 (2005).
32. Hausenloy DJ, Tsang A, Yellon DM. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc. Med. 15(2), 69-75 (2005).
33. Klingmuller U, Lorenz U, Cantley LC, Neel BG, Lodish HF. Specific recruitment of SHPTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80(5), 729-738 (1995).
34. Verdier F, Walrafen P, Hubert N et al. Proteasomes regulate the duration of erythropoietin receptor activation by controlling downregulation of cell surface receptors. J. Biol. Chem. 275(24), 18375-18381 (2000).
35. Wu H, Lee SH, Gao J, Liu X, Iruela-Arispe ML. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 126(16), 3597-3605 (1999).
36. Suzuki N, Ohneda O, Takahashi S et al. Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood 100(7), 2279-2288 (2002).
37. Wald MR, Borda ES, Sterin-Borda L. Mitogenic effect of erythropoietin on neonatal rat cardiomyocytes: signal transduction pathways. J. Cell Physiol. 167(3), 461-468 (1996).
38. Calvillo L, Latini R, Kajstura J et al. Recombinant human erythropoietin protects the myocardium from ischaemia-reperfusion injury and promotes beneficial remodeling. Proc. Natl Acad. Sci. USA 100(8), 4802-4806 (2003).
39. Parsa CJ, Matsumoto A, Kim J et al. A novel protective effect of erythropoietin in the infarcted Heart J. Clin. Invest. 112(7), 999-1007 (2003).
40. Parsa CJ, Kim J, Riel RU et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J. Biol. Chem. 279(20), 20655-20662 (2004).
41. Lipsic E, van der Meer P, Henning RH et al. Timing of erythropoietin treatment for cardioprotection in ischaemia/reperfusion. J. Cardiovasc. Pharmacol. 44(4), 473-479 (2004).
42. Shi Y, Rafiee P, Su J, Pritchard KA Jr, Tweddell JS, Baker JE. Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels. Basic Res. Cardiol. 99(3), 173-182 (2004).
43. Heidenreich S, Rahn KH, Zidek W, Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int. 39(2), 259-265 (1991).
44. 2+ mobilization and contraction in rat mesangial and aortic smooth muscle cultures. Exp. Hematol. 24(2), 392-397 (1996).
45. Sekiguchi N, Inoguchi T, Kobayashi K, Nawata H. Effect of erythropoietin on endothelial cell apoptosis induced by high glucose. Diabetes Res. Clin. Pract. 66(Suppl. 1), S103-S107 (2004).
46. Xuan YT, Guo Y, Han H, Zhu Y, Bolli R. An essential role of the JAK-STAT pathway in ischemic preconditioning. Proc. Natl Acad. Sci. USA 98(16), 9050-9055 (2001).
47. Yamaura G, Turoczi T, Yamamoto F, Siddqui MA, Maulik N, Das DK. STAT signaling in ischemic heart: a role of STAT5A in ischemic preconditioning. Am. J. Physiol. Heart Circ. Physiol. 285(2), H476-H482 (2003).
48. Mascareno E, El-Shafei M, Maulik N et al. JAK/STAT signaling is associated with cardiac dysfunction during ischaemia and reperfusion. Circulation 104(3), 325-329 (2001).
49. Bullard AJ, Govewalla P, Yellon DM. Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res. Cardiol. 100(5), 397-403 (2005).
50. Zhang J, Baines CP, Zong C et al. Functional proteomic analysis of a three-tier PKCepsilon-Akt-eNOS signaling module in cardiac protection. Am. J. Physiol. Heart Circ. Physiol. 288(2), H954-H961 (2005).
51. Rui T, Feng Q, Lei M et al. Erythropoietin prevents the acute myocardial inflammatory response induced by ischaemia/reperfusion via induction of AP-1. Cardiovasc. Res. 65(3), 719-727 (2005).
52. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399(6736), 601-605 (1999).
53. + channels during reoxygenation in guinea-pig ventricular myocytes. J Physiol. 532(Pt 1), 165-174 (2001).
54. + channels in the cardiac inner mitochondrial membrane. Science 298(5595), 1029-1033 (2002).
55. Cirillo M, Capasso G, DeSanto NG. Relationship between hematocrit and blood pressure: implications for primary hypertension. Nephron 65(4), 505-510 (1993).
56. Akimoto T, Kusano E, Ito C et al. Involvement of erythropoietin-induced cytosolic free calcium mobilization in activation of mitogen-activated protein kinase and DNA synthesis in vascular smooth muscle cells. J. Hypertens. 19(2), 193-202 (2001).
57. Gogusev J, Zhu DL, Herembert T, Ammarguellat F, Marche P, Drueke T. Effect of erythropoietin on DNA synthesis, proto-oncogene expression and phospholipase C activity in rat vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 199(2), 977-983 (1994).
58. Sabatine MS, Morrow DA, Giugliano RP et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 111(16), 2042-2049 (2005).
59. Fiordaliso F, Chimenti S, Staszewsky L et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischaemia-reperfusion injury. Proc. Natl Acad. Sci. USA. 102(6), 2046-2051 (2005).
60. Wagner KF, Katschinski DM, Hasegawa J et al. Chronic inborn erythrocytosis leads to cardiac dysfunction and premature death in mice overexpressing erythropoietin. Blood 97(2), 536-542 (2001).
61. Wexler D, Silverberg D, Blum M et al. Anemia as a contributor to morbidity and mortality in congestive heart failure. Nephrol. Dial. Transplant. 20(Suppl. 7), 11-15 (2005).
62. Opasich C, Cazzola M, Scelsi L et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anemia in patients with chronic heart failure. Eur. Heart J. Jun 29 (Epub ahead of print) (2005).
63. Silverberg DS, Wexler D, Blum M et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J. Am. Coll. Cardiol. 35(7), 1737-1744 (2000).
64. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 107(2), 223-225 (2003).
65. Volpe M, Tritto C, Testa U et al. Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am. J. Cardiol. 74(5), 468-473 (1994).
66. Okonko DO, Anker SD. Anemia in chronic heart failure: pathogenetic mechanisms. J. Card. Fail. 10(1 Suppl.), S5-S9 (2004).
67. Chatterjee B, Nydegger UE, Mohacsi P. Serum erythropoietin in heart failure patients treated with ACE-inhibitors or AT(1) antagonists. Eur. J. Heart Fail. 2(4), 393-398 (2000).
68. Muller-Ehmsen J, Schmidt A, Krausgrill B, Schwinger RH, Bloch W. Role of Erythropoetin for Angiogenesis and Vasculogenesis - from Embryonic Development through Adulthood. Am. J. Physiol. Heart Circ. Physiol. Jul 15 (Epub ahead of print) (2005).
69. George J, Goldstein E, Abashidze A et al. Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner. Cardiovasc. Res. Jul 25 [Epub ahead of print] (2005).
70. Heeschen C, Aicher A, Lehmann R et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102(4), 1340-1346 (2003).
71. Bahlmann FH, DeGroot K, Duckert T et al. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int. 64(5), 1648-1652 (2003).
72. Ribatti D, Presta M, Vacca A et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93(8), 2627-2636 (1999).
73. Carlini RG, Reyes AA, Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int. 47(3), 740-745 (1995).
74. Watanabe D, Suzuma K, Matsui S et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N. Engl. J. Med. 353(8), 782-792 (2005).
75. Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck KH. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc. Res. 64(2), 326-333 (2002).
76. Nieminen MS, Bohm M, Cowie MR et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur. Heart J. 26(4), 384-416 (2005).
77. Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 97(3), 282-289 (1998).
78. de Boer RA, van Veldhuisen DJ, van der Wijk J et al. Additional use of immunostaining for active caspase 3 and cleaved actin and PARP fragments to detect apoptosis in patients with chronic heart failure. J. Card. Fail. 6(4), 330-337 (2000).
79. Mitka M. Researchers probe anemia-heart failure link. JAMA. 290(14), 1835-1838 (2003).
80. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107(3), 363-369 (2003).
81. Wu AH, Smith A. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur. J. Heart Fail. 6(3), 355-358 (2004).
82. Campbell DJ, Woodward M, Chalmers JP et al. Prediction of heart failure by amino terminal-pro-B-type natriuretic peptide and C-reactive protein in subjects with cerebrovascular disease. Hypertension 45(1), 69-74 (2005).
83. Groenning BA, Raymond I, Hildebrandt PR, Nilsson JC, Baumann M, Pedersen F. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart 90(3), 297-303 (2004).
84. Doust JA, Pietrzak E, Dobson A, GLasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 330(7492), 625 (2005).
85. Vasan RS, Sullivan LM, Roubenoff R et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 107(11), 1486-1491 (2003).
86. Cesari M, Penninx BW, Newman AB et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 108(19), 2317-2322 (2003).
87. Yin WH, Chen JW, Jen HL et al. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am. Heart J. 147(5), 931-938 (2004).
88. Campbell DJ, Woodward M, Chalmers JP et al. Prediction of heart failure by amino terminal-pro-B-type natriuretic peptide and C-reactive protein in subjects with cerebrovascular disease. Hypertension 45(1), 69-74 (2005).
89. Alonso-Martinez JL, Llorente-Diez B, Echegaray-Agara M et al. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur. J. Heart Fail. 4(3), 331-336 (2002).
90. Tsutsui T, Tsutamoto T, Wada A et al. Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. J. Am. Coll. Cardiol. 39(6), 957-962 (2002).
91. George J, Wexler D, Roth A, Barak T, Sheps D. Keren G. Usefullness of antioxidized LDL antibody determination for assessment of clinical control in patients with heart failure. Eur. J. Heart Fail. (In Press) (2005).
92. George J, Patal S, Wexler D, Roth A, Sheps D, Keren G. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am. Heart J. (In Press) (2005).
93. Iaccarino, G, Barbato E, Cipolletta E et al. Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. Eur. Heart J. 26(17), 1752-1758 (2005).
94. Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy MO. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischaemia-reperfusion injury. FASEB J. 18(9), 1031-1033 (2004).
95. Kertesz N, Wu J, Chen TH, Sucov HM, Wu H. The role of erythropoietin in regulating angiogenesis. Dev. Biol. 276(1), 101-110 (2004).
96. Hirata A, Minamino T, Asanuma H et al. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts. Cardiovasc. Drugs Ther. 19(1), 33-40 (2005).
97. Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy MO. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischaemia-reperfusion injury. FASEB J. 18(9), 1031-1033 (2004).
98. Ananthakrishnan R, Hallam K, Li Q, Ramasamy R. JAK-STAT pathway in cardiac ischemic stress. Vascul. Pharmacol. (Epub ahead of print) (2005).
99. Hwang YC, Shaw S, Kaneko M, Redd H, Marrero MB, Ramasamy R. Aldose reductase pathway mediates JAK-STAT signaling: a novel axis in myocardial ischemic injury. FASEB J. May 19(7), 795-797 (2005).
100. Hattori R, Maulik N, Otani H et al. Role of STAT3 in ischemic preconditioning. J. Mol. Cell Cardiol. 33(11), 1929-1936 (2001).
101. Hilfiker-Kleiner D, Hilfiker A, Fuchs M et al. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ. Res. 95(2), 187-195 (2004).
102. Yoshikawa H, Powell WJ Jr, Bland JH, Lowenstein E. Effect of acute anemia on experimental myocardial ischaemia. Am. J. Cardiol. 32(5), 670-678 (1973).
103. Zeidman A, Fradin Z, Blecher A, Oster HS, Avrahami Y, Mittelman M. Anemia as a risk factor for ischemic heart disease. Isr. Med. Assoc. J. 6(1), 16-18 (2004).
104. Leist M, Ghezzi P, Grasso G et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305(5681), 239-242 (2004).
105. Brines M, Grasso G, Fiordaliso F et al. Erythropoietin mediates tissue protection through an erythropoietin and common β-subunit heteroreceptor. Proc. Natl Acad. Sci. USA 101(41), 14907-14912 (2004).
106. Perloff JK, Rosove MH, Child JS, Wright GB. Adults with cyanotic congenital heart disease: hematologic management. Ann. Intern. Med. 109(5), 406-413 (1988).
107. Bassenge E, Munzel T. Consideration of conduit and resistance vessels in regulation of blood flow. Am. J. Cardiol. 62(8), 40-44 (1988).
108. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc. Natl Acad. Sci. USA 87(15), 5978-5982 (1990).
109. Haroon ZA, Amin K, Jiang X, Arcasoy MO. A novel role for erythropoietin during fibrin-induced wound-healing response. Am. J. Pathol. 163(3), 993-1000 (2003).
110. Yasuda Y, Masuda S, Chikuma M, Inoue K, Nagao M, Sasaki R. Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J. Biol. Chem. 273(39), 25381-25387 (1998).